October 22, 2014 8:17 PM ET

Software

Company Overview of Appistry Inc.

Company Overview

Appistry Inc. provides analytics and data management solutions to corporations, Fortune 100 companies, and government agencies worldwide. It offers Ayrris, an open, scalable solution for data-intensive applications. The company also provides AYRRIS/BIO–NGS Analytics that employs analytical pipelines designed to automate the analysis and management of specific types of data; and AYRRIS/BIO–Data Management, which provides data management solutions adapted to support NGS Analytics for the life sciences sector. In addition, it offers Ayrris/DEFENSE that offers high-volume data ingest, storage, analysis, and delivery for the intelligence and defense organizations; Appistry CloudDx, a cloud-based ...

10845 Olive Boulevard

Suite 260

St. Louis, MO 63141

United States

Founded in 2001

Phone:

314-336-5080

Fax:

314-336-5086

Key Executives for Appistry Inc.

Chairman
Age: 57
Co-Founder
Co-Founder
Co-Founder
Co-Founder
Compensation as of Fiscal Year 2014.

Appistry Inc. Key Developments

Appistry Inc. Appoints Cornelius (Neal) Boerkoel as Chief Medical Officer

Appistry Inc. announced that Cornelius (Neal) Boerkoel has joined Appistry's management team as the company's first chief medical officer. A former laboratory director at the NIH Undiagnosed Diseases Program and co-founder of the Rare Disease Foundation, Boerkoel brings more than 30 years of research and clinical expertise to Appistry, where he will actively participate in developing the company's long-term corporate and product strategy while building relationships with scientific partners and customers. Neal will retain his appointments at the Children's and Women's Medical Centre of British Columbia and the University of British Columbia, where he is a clinical associate professor and clinical investigator in the Provincial Medical Genetics Program and Child and Family Research Institute.

Appistry Teams with Personal Genome Diagnostics to Offer CancerSelect Test through Appistry CloudDx

Appistry, Inc. announced an agreement with Personal Genome Diagnostics to include the company's CancerSelect(TM) panel in Appistry's recently released Appistry CloudDx(TM) genomics testing service. PGDx is among the first organizations to offer lab-developed tests (LDTs) through Appistry's cloud-based service that makes LDTs from leading diagnostic test providers available to physicians across the United States. CancerSelect targets 120 genes of clinical and biological importance to cancer, providing information that can help physicians individualize treatment to a patient's cancer. The CancerSelect panel is sequenced in PGDx's CLIA-certified laboratory, and the analysis is conducted using PGDx's proprietary algorithms that provide extremely high coverage, copy number analyses for 63 genes, and translocation analysis for 17 genes. Appistry will collaborate with PGDx to deliver a report to participating physicians containing a pathological evaluation of the tumor sample; tumor-specific mutations (alterations and substitutions, amplifications, and translocations); a description of mutated genes and pathways along with biologic and clinical implications; full statistics; and therapeutic, predictive, and prognostic information and references, as well as referral information for ongoing clinical trials that might be relevant based on the analysis results. Appistry CloudDx streamlines and simplifies the workflow associated with genomics-based testing, which has been limited in its impact, partly because it requires organizations to amass infrastructure and expertise to deliver relevant results that are usable by physicians. Appistry CloudDx provides a single web dashboard for ordering and tracking the progress of tests and orchestrates the data flow between test providers such as PGDx and requesting physicians and hospitals, thereby ensuring that data and physical samples are transferred and securely managed in accordance with HIPAA and CLIA guidelines.

Appistry, Inc. Launches Appistry CloudDx(TM)

Appistry Inc. announced the launch of Appistry CloudDx(TM), a cloud-based service for ordering genomics tests. By collecting established laboratory-developed tests (LDTs) in a single, easy-to-access environment and streamlining the processes associated with delivering clinically relevant results to physicians, Appistry CloudDx aims to place the genomically enhanced medicine now practiced at academic medical centers within the reach of community physicians and regional hospitals. Appistry CloudDx provides a web-based dashboard for ordering established LDTs and tracking the status of individual orders across healthcare organizations. The cloud based system orchestrates the flow of data and logistics among the network of service providers often needed to sequence samples, analyze sequencing data, and interpret the results for physicians. This orchestration ensures that data and physical samples are transferred and securely managed in accordance with HIPAA and CLIA guidelines and that all processes essential for the rapid delivery of results to physicians occur consistently and efficiently. Appistry CloudDx will include established LDTs from diagnostic test providers covering a range of diseases. Currently, the system includes panels and tests for cardiomyopathy, hearing loss, lung disease, and whole genome sequencing developed by Partners HealthCare Personalized Medicine. Additional tests and test partners will be announced in the coming weeks. It is estimated that approximately 80—90% of oncology occurs in a community setting. Yet these physicians are the least likely to have access to the infrastructure to support genomics testing or the expertise to apply it to patient care. For genomics to become a routine part of disease diagnosis and treatment, all physicians - regardless of geography, institutional size, or medical system affiliation - need easy ways to access tests and receive relevant results. Additionally, the simplified workflow provided by Appistry CloudDx will enable hospitals to begin measuring and quantifying how genomics tests improve patient care and outcomes. Evidence of improved patient care and cost reductions due to genomics testing will be key in convincing insurance companies to cover the services.

Similar Private Companies By Industry

Company Name Region
CT3, Inc. United States
Tachyus Corp United States
Financial Crime Check LLC United States
TouchTunes Music Corporation United States
Innovapeak Ltd. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Appistry Inc., please visit www.appistry.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.